I’ve been reading HC ANP for longer than a month and been a shareholder for much longer than that. The $$$$ shill circle jerk posting here is very obvious. Itsa was talking about commercialisation next year which then become 2023. Well the CR presentation gives the timeline date for marketing approval/commercialisation as end of 2025. I’ve not known too many biotechs that have beaten their schedules and delivered before time. And I’m well aware of the $US 500 mill CR from Sarepta last month. Was just making the point that it is rare for deals in new drugs after a 9 patient phase 2a study and four years until commercialisation assuming they jump over futility analysis and meet endpoints on trial about to commence.
ANP Price at posting:
24.8¢ Sentiment: Hold Disclosure: Held
